Inflammatory Stratification in Primary Sjögren's Syndrome Reveals Novel Immune Cell Alterations in Patients' Minor Salivary Glands.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 28 04 2021
accepted: 24 06 2021
entrez: 29 7 2021
pubmed: 30 7 2021
medline: 22 12 2021
Statut: epublish

Résumé

There is a critical need to deconvolute the heterogeneity displayed by the minor salivary glands of primary Sjögren's syndrome (pSS) patients. This is challenging primarily because the disease etiology remains unknown. The hypothesis includes that initial events in the disease pathogenesis target the salivary glands, thereby triggering the development of focal infiltrates (≥50 mononuclear cells) and finally germinal center-like structures. However, the proportion of key mononuclear immune cells residing at these sites, in combination with the overall ratio of morphometric tissue atrophy and adipose infiltration within the minor salivary glands (MSG) parenchyma at distinct phases of inflammatory disease establishment and progression have not been quantified in detail. In this cross-sectional study, we intended to address this problem by stratifying 85 patients into mild (S1), moderate (S2), and severe (S3) stages using the Inflammatory severity index. We found that mild (<3%) and marked (≥3%) levels of atrophy were accompanied by the respective levels of adipose infiltration in the non-SS sicca controls (

Identifiants

pubmed: 34322130
doi: 10.3389/fimmu.2021.701581
pmc: PMC8311440
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

701581

Informations de copyright

Copyright © 2021 Bharaj, Aqrawi, Fromreide, Jonsson, Brun, Appel and Skarstein.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Clin Immunol. 2013 May;147(2):95-104
pubmed: 23578551
J Immunol. 2017 Oct 15;199(8):2745-2757
pubmed: 28904129
Arthritis Rheumatol. 2018 Sep;70(9):1481-1488
pubmed: 29669392
J Korean Med Sci. 2016 Feb;31(2):190-5
pubmed: 26839471
Int J Rheum Dis. 2017 Feb;20(2):245-251
pubmed: 28556615
Ann Rheum Dis. 2017 Jul;76(7):1161-1168
pubmed: 27965259
Arthritis Rheum. 2006 Jul;54(7):2280-8
pubmed: 16802367
Ann Rheum Dis. 2008 Jul;67(7):949-54
pubmed: 17962240
Ann Rheum Dis. 2011 Aug;70(8):1363-8
pubmed: 21715359
Lupus. 2010 Feb;19(2):138-45
pubmed: 19952070
Nat Rev Rheumatol. 2010 Sep;6(9):529-37
pubmed: 20683439
Scand J Immunol. 2018 Jun 8;:e12679
pubmed: 29882349
Ann Rheum Dis. 2002 Jun;61(6):554-8
pubmed: 12006334
Arthritis Rheum. 2006 Jul;54(7):2295-9
pubmed: 16802369
Clin Exp Rheumatol. 1998 Jan-Feb;16(1):63-5
pubmed: 9543564
Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):80-88
pubmed: 29148407
Autoimmunity. 2018 May;51(3):135-146
pubmed: 29504848
Autoimmunity. 2017 Dec;50(8):451-457
pubmed: 28988489
Sci Rep. 2017 Sep 19;7(1):11897
pubmed: 28928382
J Clin Pathol. 1986 Apr;39(4):406-17
pubmed: 3700674
Arthritis Care Res (Hoboken). 2012 Apr;64(4):475-87
pubmed: 22563590
J Oral Pathol Med. 2008 Oct;37(9):515-21
pubmed: 18662248
Rom J Morphol Embryol. 2017;58(2):409-417
pubmed: 28730224
J Rheumatol. 2007 Oct;34(10):2044-9
pubmed: 17787040
Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):27-33
pubmed: 33095140
Int J Clin Exp Pathol. 2014 Apr 15;7(5):1988-96
pubmed: 24966908
Arthritis Rheum. 2011 Jul;63(7):2021-30
pubmed: 21480190
Arthritis Res Ther. 2011 Jan 07;13(1):R2
pubmed: 21214903
J Autoimmun. 2010 Jun;34(4):400-7
pubmed: 19889514
Ann Rheum Dis. 2017 Oct;76(10):1781-1784
pubmed: 28710097
J Autoimmun. 1989 Aug;2(4):553-8
pubmed: 2789657
Autoimmunity. 2016 Aug;49(5):338-46
pubmed: 27206986
J Rheumatol. 2014 Nov;41(11):2214-22
pubmed: 25274895
Rheumatology (Oxford). 2009 Sep;48(9):1102-6
pubmed: 19574472
J Rheumatol. 2013 Sep;40(9):1566-71
pubmed: 23908448
Front Immunol. 2020 Oct 19;11:594096
pubmed: 33193443

Auteurs

Tamandeep K Bharaj (TK)

Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Lara A Aqrawi (LA)

Department of Health Sciences, Kristiania University College, Oslo, Norway.

Siren Fromreide (S)

Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Roland Jonsson (R)

Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Department of Rheumatology, Haukeland University Hospital, Bergen, Norway.

Johan G Brun (JG)

Department of Rheumatology, Haukeland University Hospital, Bergen, Norway.

Silke Appel (S)

Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.

Kathrine Skarstein (K)

Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Department of Pathology, Haukeland University Hospital, Bergen, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH